Inflammatory mediators and oxidative stress pathways

Inflammatory mediators and oxidative stress pathways represent a broad category of interconnected biological processes rather than a single molecular target. Inflammatory mediators, including cytokines, chemokines, and lipid signaling molecules like prostaglandins, coordinate the body's response to injury or infection, while oxidative stress refers to an imbalance between the production of reactive oxygen species (ROS) and the ability of biological systems to detoxify these reactive intermediates. These two processes are mutually reinforcing; oxidative stress can activate pro-inflammatory transcription factors like NF-κB, while inflammatory cells release ROS as part of the immune response, creating a vicious cycle of tissue damage (Hussain et al., 2016, NIH/PubMed). Chronic activation of these pathways is a hallmark of various pathologies, including cardiovascular disease, neurodegeneration, and cancer. Therapeutic strategies often target specific nodes within these pathways, such as inhibiting the enzyme COX-2 or activating the antioxidant master regulator Nrf2 (Wardyn et al., 2015, PubMed). Because this term encompasses a vast array of receptors, enzymes, and signaling cascades, it is classified as a biological pathway or process rather than a discrete, druggable therapeutic target for drug development.

Other names

Inflammation and oxidative stress signalingRedox-inflammatory pathwaysPro-inflammatory and pro-oxidant signaling cascades

Modulation of these pathways typically involves the inhibition of pro-inflammatory signaling molecules (e.g., cytokines, cyclooxygenases) or the enhancement of antioxidant defense mechanisms (e.g., Nrf2 activation) to restore physiological homeostasis and prevent tissue damage caused by reactive oxygen species.